

Concluding Remarks¹

Norman Zamcheck and Glenn Steele, Jr.

Gastrointestinal Research Laboratory, Mallory Institute of Pathology Foundation, Boston City Hospital, Boston, Massachusetts 02118

This workshop has shown us that radioimmuno-detection is not a new field. It has a firm scientific footing to which many of the authors of this supplement have contributed, including Drs. Pressman, Bale, and Bagshawe who were there at its beginnings. It is also an extension of the enormous amount of work done on tumor markers by many of the participants in this workshop during the past 10 or more years. Dr. Phil Gold gave the field a great clinical push forward 10 years ago and now Dr. David Goldenberg and his team have provided the watershed studies which point toward potential clinical usefulness. There was resistance to the clinical application of "tumor markers" in general and to CEA in particular and a

similar reaction will surely rise against radioimmuno-detection. The record to date indicates that the initial clinical studies can be done with apparent safety. Preliminary confirmation has been provided by others, and questions requiring further study are being defined.

Investigations, both basic and clinical, should now proceed in a systematic and orderly manner, hand in hand with parallel developments in related fields of biomedical science and technology. Methods must be developed or refined. Reagents need to be standardized, and alternative approaches compared. Guidelines and protocols are needed. Communication and collaborations are just beginning.

This workshop has taken the first step. We all express our gratitude to Dr. Goldenberg and his associates for bringing us together and we look forward to the second.

¹ Presented at the UICC Workshop on Radioimmuno-detection of Cancer, July 19 to 21, 1979, Lexington, Ky.